Understand the critical impact of recent US biotech policy changes on 2026 event agendas. This briefing offers a 4-point analysis of regulatory shifts, funding landscapes, and strategic adjustments for industry stakeholders.

Key policy discussions from US biotech events in the last half of 2024 are shaping the industry's trajectory for 2025, focusing on regulatory frameworks, investment incentives, and ethical considerations.